Brielle Benyon

The Food and Drug Administration approved Krazati plus Erbitux for pretreated KRAS G12C-mutant colorectal cancer.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

Patients who received systemic therapy at the end of life did not have longer overall survival averages than those who did not receive therapy at end of life.

The Food and Drug Administration approved Keytruda plus chemotherapy, followed by single-agent Keytruda for primary advanced or recurrent endometrial cancer.

To ensure best outcomes, patients with chronic myeloid leukemia should maintain frequent communication with their care teams — even between appointments.

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said.

The FDA approved Blincyto for patients aged one month and older with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

A chronic myeloid leukemia diagnosis can negatively affect patients and their loved ones’ mental health, but there are resources that can help.

The FDA approved Imfinzi plus carboplatin and paclitaxel followed by Imfinzi alone in patients with primary advanced or recurrent dMMR endometrial cancer.

From Kate Middleton giving an update on her cancer treatment to Kevin Jonas’ skin cancer surgery, here’s what’s happening in the oncology space this week.

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

The Food and Drug Administration approved Augtyro for patients over the age of 12 with NTRK-positive solid tumors.

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis.

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.

The Food and Drug Administration will speed up their review and potential approval of Tagrisso for certain patients with EGFR-mutant lung cancer.

Patients with resectable stage 3 melanoma should talk about pretreatment therapy with their cancer care teams, an expert said.

From the NBA’s Alonzo Mourning opening up about his prostate surgery to an actor from “Felicity” dying of cancer, here’s what is happening in the oncology space this week.

Trodelvy led to better disease control and improved quality of life compared to chemotherapy in patients with triple-negative breast cancer.

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said.

After a cancer diagnosis, toxic positivity can be unhelpful, though forced joy may bring light to a difficult situation, a survivor and advocate said.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells.

Presurgical paclitaxel, Herceptin and Perjeta showed “incredible efficacy” in treatment of HER2-positive breast cancer.

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

An Adcetris-based treatment regimen improved progression-free survival and was more tolerable for patients with classical Hodgkin lymphoma.

From NBA Hall of Famer Bill Walton dying from cancer to an ancient skull showing evidence of early cancer treatments, here’s what’s happening in the oncology space this week.